Rocco Palermo

List of Publications by Year
in descending order

37 papers	1,314 citations	279798 23 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	2277 citing authors

#	Article	IF	Citations
1	Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 2324-2335.	7.2	147
2	Notch3 and pre-TCR interaction unveils distinct NF-Î¹B pathways in T-cell development and leukemia. EMBO Journal, 2006, 25, 1000-1008.	7.8	130
3	PKCÎ¸ mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene, 2005, 24, 992-1000.	5.9	67
4	The archaeal eIF2 homologue: functional properties of an ancient translation initiation factor. Nucleic Acids Research, 2005, 33, 1804-1812.	14.5	67
5	Acetylation controls Notch3 stability and function in T-cell leukemia. Oncogene, 2012, 31, 3807-3817.	5.9	54
6	Notch3/Jagged1 Circuitry Reinforces Notch Signaling and Sustains T-ALL. Neoplasia, 2014, 16, 1007-1017.	5.3	45
7	Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38Î± modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Letters, 2014, 344, 110-118.	7.2	45
8	Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. Oncogene, 2016, 35, 4741-4751.	5.9	45
9	Identification of a novel chalcone derivative that inhibits Notch signaling in T-cell acute lymphoblastic leukemia. Scientific Reports, 2017, 7, 2213.	3.3	42
10	NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: Implications for Huntington's disease. Neuroscience Letters, 2008, 434, 241-246.	2.1	40
11	Protective effect of pioglitazone, a PPARÎ³ ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Research Bulletin, 2011, 85, 231-237.	3.0	39
12	Notch signaling as a therapeutic target for acute lymphoblastic leukemia. Expert Opinion on Therapeutic Targets, 2018, 22, 331-342.	3.4	39
13	NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. Oncogenesis, 2018, 7, 42.	4.9	39
14	Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood, 2006, 107, 3313-3320.	1.4	37
15	Maml1 acts cooperatively with Gli proteins to regulate sonic hedgehog signaling pathway. Cell Death and Disease, 2017, 8, e2942-e2942.	6.3	36
16	Loss of Notch1-dependent p21^{Waf1/Cip1}expression influences the Notch1 outcome in tumorigenesis. Cell Cycle, 2014, 13, 2046-2245.	2.6	33
17	Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression. Leukemia, 2013, 27, 485-488.	7.2	32
18	The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2014, 1839, 813-825.	1.9	32

#	Article	IF	Citations
19	The Molecular Basis of Notch Signaling Regulation: A Complex Simplicity. Current Molecular Medicine, 2014, 14, 34-44.	1.3	32
20	Histone Modifications Drive Aberrant Notch3 Expression/Activity and Growth in T-ALL. Frontiers in Oncology, 2019, 9, 198.	2.8	29
21	Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia. Oncogene, 2010, 29, 1463-1474.	5.9	27
22	The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPÎ±. Leukemia, 2015, 29, 2442-2445.	7.2	27
23	Regulation of proapoptotic proteins Bak1 and p53 by miR-125b in an experimental model of Alzheimer's disease: Protective role of 17Î²-estradiol. Neuroscience Letters, 2016, 629, 234-240.	2.1	27
24	Manipulation of lipoplex concentration at the cell surface boosts transfection efficiency in hard-to-transfect cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 681-691.	3.3	25
25	Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance. Cancer Research, 2019, 79, 5575-5586.	0.9	24
26	Chalcones and Chalcone-mimetic Derivatives as Notch Inhibitors in a Model of T-cell Acute Lymphoblastic Leukemia. ACS Medicinal Chemistry Letters, 2019, 10, 639-643.	2.8	23
27	The loss of ATP2C1 impairs the DNA damage response and induces altered skin homeostasis: Consequences for epidermal biology in Hailey-Hailey disease. Scientific Reports, 2016, 6, 31567.	3.3	21
28	Natural Products Inspired Modulators of Cancer Stem Cells-specific Signaling Pathways Notch and Hedgehog. Current Pharmaceutical Design, 2019, 24, 4251-4269.	1.9	21
29	PLK1 targets NOTCH1 during DNA damage and mitotic progression. Journal of Biological Chemistry, 2019, 294, 17941-17950.	3.4	16
30	Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives. Cancers, 2021, 13, 5106.	3.7	16
31	DNA Damage Stress: Cui Prodest?. International Journal of Molecular Sciences, 2019, 20, 1073.	4.1	15
32	Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response. Oncogenesis, 2020, 9, 93.	4.9	13
33	Effect ofArgania spinosaoil extract on proliferation and Notch1 and ERK1/2 signaling of T-cell acute lymphoblastic leukemia cell lines. Food and Agricultural Immunology, 2016, 27, 350-357.	1.4	8
34	The Notch3 Receptor and Its Intracellular Signaling-Dependent Oncogenic Mechanisms. Advances in Experimental Medicine and Biology, 2018, 1066, 205-222.	1.6	8
35	Numb-dependent integration of pre-TCR and p53 function in T-cell precursor development. Cell Death and Disease, 2014, 5, e1472-e1472.	6.3	6
36	When Viruses Cross Developmental Pathways. Frontiers in Cell and Developmental Biology, 2021, 9, 691644.	3.7	5

#	Article	IF	Citations
37	5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance. Frontiers in Oncology, 0, 12, .	2.8	2